Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Common Equity (2016 - 2025)

Bioadaptives' Common Equity history spans 8 years, with the latest figure at -$2.1 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 45.5% to -$2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 million, a 45.5% decrease, with the full-year FY2025 number at -$2.1 million, down 45.5% from a year prior.
  • Common Equity hit -$2.1 million in Q4 2025 for Bioadaptives, down from -$1.5 million in the prior quarter.
  • Over the last five years, Common Equity for BDPT hit a ceiling of -$1.0 million in Q1 2021 and a floor of -$2.1 million in Q4 2025.
  • Historically, Common Equity has averaged -$1.5 million across 5 years, with a median of -$1.5 million in 2022.
  • Biggest five-year swings in Common Equity: plummeted 57.56% in 2024 and later skyrocketed 34.07% in 2025.
  • Tracing BDPT's Common Equity over 5 years: stood at -$1.1 million in 2021, then tumbled by 32.79% to -$1.5 million in 2022, then dropped by 13.44% to -$1.6 million in 2023, then grew by 11.1% to -$1.5 million in 2024, then plummeted by 45.5% to -$2.1 million in 2025.
  • Business Quant data shows Common Equity for BDPT at -$2.1 million in Q4 2025, -$1.5 million in Q3 2025, and -$1.2 million in Q2 2025.